These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35523485)

  • 21. Cell number per spheroid and electrical conductivity of nanowires influence the function of silicon nanowired human cardiac spheroids.
    Tan Y; Richards D; Coyle RC; Yao J; Xu R; Gou W; Wang H; Menick DR; Tian B; Mei Y
    Acta Biomater; 2017 Mar; 51():495-504. PubMed ID: 28087483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial.
    Wiberg S; Kjaergaard J; Møgelvang R; Møller CH; Kandler K; Ravn H; Hassager C; Køber L; Nilsson JC
    BMJ Open; 2021 Nov; 11(11):e052340. PubMed ID: 34740932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ion Channel Expression and Electrophysiology of Singular Human (Primary and Induced Pluripotent Stem Cell-Derived) Cardiomyocytes.
    Schmid C; Abi-Gerges N; Leitner MG; Zellner D; Rast G
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biophysical comparison of sodium currents in native cardiac myocytes and human induced pluripotent stem cell-derived cardiomyocytes.
    Goodrow RJ; Desai S; Treat JA; Panama BK; Desai M; Nesterenko VV; Cordeiro JM
    J Pharmacol Toxicol Methods; 2018; 90():19-30. PubMed ID: 29128504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
    Borow KM; Yaroshinsky A; Greenberg B; Perin EC
    Circ Res; 2019 Jul; 125(3):265-281. PubMed ID: 31318648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Changes in Morphology and Function of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (HiPSC-CMs) Cultured on an Aligned-Nanofiber Cardiac Patch.
    Khan M; Xu Y; Hua S; Johnson J; Belevych A; Janssen PM; Gyorke S; Guan J; Angelos MG
    PLoS One; 2015; 10(5):e0126338. PubMed ID: 25993466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform.
    Sharma A; Marceau C; Hamaguchi R; Burridge PW; Rajarajan K; Churko JM; Wu H; Sallam KI; Matsa E; Sturzu AC; Che Y; Ebert A; Diecke S; Liang P; Red-Horse K; Carette JE; Wu SM; Wu JC
    Circ Res; 2014 Aug; 115(6):556-66. PubMed ID: 25015077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patch-Clamp Recording from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Improving Action Potential Characteristics through Dynamic Clamp.
    Verkerk AO; Veerman CC; Zegers JG; Mengarelli I; Bezzina CR; Wilders R
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28867785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-Cell Transcriptomics of Engineered Cardiac Tissues From Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Abnormal Developmental Trajectory and Intrinsic Contractile Defects in Hypoplastic Right Heart Syndrome.
    Lam YY; Keung W; Chan CH; Geng L; Wong N; Brenière-Letuffe D; Li RA; Cheung YF
    J Am Heart Assoc; 2020 Oct; 9(20):e016528. PubMed ID: 33059525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case-control, phase I/II trial.
    Hoang DM; Nguyen KT; Nguyen AH; Nguyen BN; Nguyen LT
    BMJ Open; 2021 May; 11(5):e045788. PubMed ID: 33986057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
    Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
    Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening.
    Sharma A; Wu JC; Wu SM
    Stem Cell Res Ther; 2013 Dec; 4(6):150. PubMed ID: 24476344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.
    Menkis AH; Martin J; Cheng DC; Fitzgerald DC; Freedman JJ; Gao C; Koster A; Mackenzie GS; Murphy GJ; Spiess B; Ad N
    Innovations (Phila); 2012; 7(4):229-41. PubMed ID: 23123988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
    Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
    Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application.
    Ito E; Miyagawa S; Takeda M; Kawamura A; Harada A; Iseoka H; Yajima S; Sougawa N; Mochizuki-Oda N; Yasuda S; Sato Y; Sawa Y
    Sci Rep; 2019 Feb; 9(1):1881. PubMed ID: 30760836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
    Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
    Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional coculture of sympathetic neurons and cardiomyocytes derived from human-induced pluripotent stem cells.
    Winbo A; Ramanan S; Eugster E; Jovinge S; Skinner JR; Montgomery JM
    Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H927-H937. PubMed ID: 32822546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human embryonic stem cells vs human induced pluripotent stem cells for cardiac repair.
    Barad L; Schick R; Zeevi-Levin N; Itskovitz-Eldor J; Binah O
    Can J Cardiol; 2014 Nov; 30(11):1279-87. PubMed ID: 25442431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.